Gilead Sciences signs licencing agreements with six companies to manufacture, commercialise Lenacapavir Read more
Merck to initiate new clinical programme with lower dose of daily oral Islatravir in combination with Doravirine for HIV-1 treatment Read more
Gilead and Merck initiate phase-II study on Lenacapavir and Islatravir oral combo for HIV-1 treatment in virologically suppressed adults Read more